Colorectal Cancer Clinical Trial
Official title:
Colorectal Cancer Prehabilitation in Changi General Hospital
Verified date | December 2021 |
Source | Changi General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cancer prehabilitation typically involves multiple pre-op visits. The investigators aim to assess the impact of their novel model, a "one-stop "service by a small, "levelled-up" core team on newly diagnosed colorectal cancer patients planned for surgery.
Status | Completed |
Enrollment | 59 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. All newly diagnosed colorectal cancer patients planned for surgery in Changi General Hospital, Singapore Exclusion Criteria: 1. Patients' refusal to participate |
Country | Name | City | State |
---|---|---|---|
Singapore | Changi General Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
Changi General Hospital |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6-minute-walk-test | Distance walked in 6 minutes under standardised conditions | Baseline | |
Primary | 6-minute-walk-test | Distance walked in 6 minutes under standardised conditions | Pre-Operatively (after prehabilitation) | |
Primary | 6-minute-walk-test | Distance walked in 6 minutes under standardised conditions | Post-Operatively (3 months) | |
Secondary | 30-second-sit-to-stand-test | Number of repetitions of sit-to-stand within 30 seconds | Baseline | |
Secondary | 30-second-sit-to-stand-test | Number of repetitions of sit-to-stand within 30 seconds | Pre-Operatively (after prehabilitation) | |
Secondary | 30-second-sit-to-stand-test | Number of repetitions of sit-to-stand within 30 seconds | Post-Operatively (3 months) | |
Secondary | Hospital Anxiety and Depression Scale | Divided into Anxiety (0-21 points) and Depression scale (0-21 points), the higher the worser | Baseline | |
Secondary | Hospital Anxiety and Depression Scale | Divided into Anxiety (0-21 points) and Depression scale (0-21 points), the higher the worser | Pre-Operatively (after prehabilitation) | |
Secondary | Hospital Anxiety and Depression Scale | Divided into Anxiety (0-21 points) and Depression scale (0-21 points), the higher the worser | Post-Operatively (3 months) | |
Secondary | EuroQol- 5 Dimension | Health Score (visual analogue scale from 0-100), the higher the better | Baseline | |
Secondary | EuroQol- 5 Dimension | Health Score (visual analogue scale from 0-100), the higher the better | Post-Operatively (3 months) | |
Secondary | Post-Operative Hospital Length of Stay | Post-Operative Hospital Length of Stay | From Date of Admission for Surgery till Date of Discharge, assessed up to 100 weeks | |
Secondary | 30-Day Post-Operative Major Complications | 30-Day Post-Operative Major Complications | From Surgery till 30 Days Post-op | |
Secondary | 30-Day Post-Operative Readmission Rates | 30-Day Post-Operative Readmission Rates | From Surgery till 30 Days Post-op | |
Secondary | 30-Day Post-Operative Mortality | 30-Day Post-Operative Mortality | From Surgery till 30 Days Post-op | |
Secondary | Patient Satisfaction Survey | Patient Satisfaction Survey | Pre-Operatively (after prehabilitation) | |
Secondary | Patient Satisfaction Survey | Patient Satisfaction Survey | Post-Operatively (3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |